Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma

Abstract

Early, sustained alterations in LV structure and function occur in children with sarcoma after high-dose doxorubicin, with adverse changes and protective effects of dexrazoxane more pronounced in females as compared with males. Dexrazoxane may have sex-specific cardioprotective effects.